DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Virtual Event

2020年8月18日 (火) 午前 8:00 - 2020年8月19日 (水) 午後 3:45

(US Eastern Standard Time)

Fort Washington, PA 19034

Digital Technology in Clinical Trials

Session 2 Track 2: Implications of Regulatory Requirements From the Digital Tool Regulators of Health Authorities

Session Chair(s)

Paul  Upham

Paul Upham

Head, Smart Devices

Roche / Genentech, United States

As new digital health tools (e.g., digital endpoints / biomarkers, etc.) are being developed and introduced into drug clinical trials and launched commercially, health authority regulators are seeking to ensure their safety and efficacy. While there is a growing consensus amongst regulators about how to classify and assess the risk of these new digital tools, there is significant variation across markets and geographies that is critical for the developers and users of these tools to understand. The compliance requirements differ depending on the market, the types and classes of tools (SaMD, sensors, etc.) and can have a significant impact on their development and the execution of the clinical trials that are using them.

Learning Objective :

At the conclusion of this session, participants should be able to:

  • Understand the similarities and differences in digital health tool regulations between key regions
  • Describe the different compliance activities required for the development and use of these tools in clinical trialsUnderstand how to optimize your compliance activities when your digital tool is deployed in multiple countries

Speaker(s)

Michael  Benecky, PhD

Regulatory Considerations During Digital Clinical Innovation

Michael Benecky, PhD

UCB, United States

Senior Director, Global Regulatory Affairs

Seya  Colloud, PharmD

Addressing regulators Needs While Conducting Clinical Studies with Digital Health Tools in Europe

Seya Colloud, PharmD

F. Hoffmann-La Roche Ltd, Switzerland

Global Regulatory Director

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。